NetworkNewsBreaks – India Globalization Capital
Post# of 436
(Total Views: 1513)
Posted On: 09/01/2017 4:50:51 PM
NetworkNewsBreaks – India Globalization Capital (NYSE: IGC) a Dark Horse in the Race to Treat Alzheimer’s
Alzheimer’s is the most expensive disease in the United States, and pharmaceutical companies are racing to find viable treatments for this devastating disease, which currently affects more than 5.3 million Americans and their loved ones. Wall Street is placing bets on who will win the race to treat Alzheimer’s, and India Globalization Capital (NYSE MKT: IGC) is one promising candidate with a compelling patent-pending treatment protocol. An excerpt from an article further discussing this reads: “IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics includes treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease. IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Alzheimer’s is the most expensive disease in the United States, and pharmaceutical companies are racing to find viable treatments for this devastating disease, which currently affects more than 5.3 million Americans and their loved ones. Wall Street is placing bets on who will win the race to treat Alzheimer’s, and India Globalization Capital (NYSE MKT: IGC) is one promising candidate with a compelling patent-pending treatment protocol. An excerpt from an article further discussing this reads: “IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics includes treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease. IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)